INTRODUCTION

Head and neck cancer is the seventh most common malignant tumour in the world, with more than 5.5 million cases diagnosed and 379,000 deaths globally in 2015.1 Oral squamous cell carcinoma (OSCC) is the most common oral cancer, accounting for 80%-90% of head and neck cancer.2 Although chemotherapy and targeted therapy for the treatment of OSCC has been developed rapidly in the past years, the overall 5-year survival rate for OSCC patients still remains at 50% due to the metastases and/or second tumours arising in patients following treatment.3 Therefore, the development of a safe and effective treatment strategy for OSCC is urgently needed.

Drug repositioning has recently drawn considerable attention as an approach used to identify alternative therapeutic uses of compounds that have failed in the development phase or to expand the use of drugs that are already in use.4 This approach has been widely...
applied to determine primary treatments for rare tumours lacking effective treatments and/or to develop secondary treatments for recurrent diseases.\(^5\) Recently, non-oncological drugs including thalidomide have been repurposed as anticancer drugs\(^6\) and related clinical trials are underway. Furthermore, various drugs such as oxycodone, enalaprilat, itraconazole, nelfinavir, disulfiram, digoxin and metformin, which were previously used for various purposes, have been repurposed as anticancer drugs, which are now being tested in clinical trials.\(^6\)

Statins, also known as 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, are widely used to treat high-cholesterol patients via inhibition of cholesterol biosynthesis. Recently, the clinical benefits of statins have been demonstrated in the treatment of cancers such as lung, prostate and colon cancers; therefore, statins have drawn interest as potent anticancer drugs.\(^7\)-\(^9\) In patients with head and neck cancer plus hyperlipidaemia, the intake of statins demonstrated higher overall survival of 2 years compared to patients with hyperlipidaemia without statin intake.\(^10\) A previous cohort study also showed that the use of statins in patients with primary inflammatory breast cancer improved their disease-free survival.\(^11\)

The molecular mechanism underlying the anticancer effects of statins have been studied and known to be mediated via broad regulation of cell proliferation, cell cycle, apoptosis, migration, invasion and metastasis.\(^12\) In particular, statins inhibit ovarian cancer cell proliferation and induce apoptosis by reducing the enzymatic activity of HMG-CoA reductase, which is an important enzyme required for cholesterol synthesis in the mevalonate pathway.\(^13\) In addition, statins activate AMPK, a cellular energy sensor that maintains metabolic homeostasis under stress conditions,\(^14\),\(^15\) and the activation of which is involved in the induction of apoptosis and suppression of cell viability in cancer cells.\(^14\)

Furthermore, statins deactivate the PI3K/Akt/mTOR, and MAPK/ERK signalling, thereby leading to apoptosis and suppression of breast cancer cell proliferation.\(^16\) Although statins show anticancer effect in many cancers, there has been still insufficient data to demonstrate the effects of statins on OSCC and further discovery of statin with higher potency and better toxicity profile is needed for the future clinical trial.

FOXO3a, a protein of the Forkhead box class O (FOXO) subfamily, is a transcription factor that regulates multiple physiological and pathological processes such as proliferation, cell cycle progression, cell survival, DNA damage and apoptosis.\(^17\) Kinases such as Akt, ERK, SGK and IKK\(_\beta\) facilitate the nuclear export of FOXO3a via phosphorylation, which leads to ubiquitination and subsequent proteasomal degradation of FOXO3a.\(^18\) However, phosphorylation of FOXO3a by AMPK and MST1 facilitates nuclear translocation, thereby mediating multiple cellular processes by inducing the transcription of its target genes.\(^19\) In particular, FOXO3a transcriptionally induces Bim, Fas ligand (Fasl) and p53 up-regulated modulator of apoptosis (PUMA), thereby leading to apoptotic processes.\(^20\),\(^21\) Since FOXO3a induces genes relating to apoptosis, it has been regarded as a tumour suppressor, and the expression level of FOXO3a has been found to decrease in various malignant tumours. For example, low expression of FOXO3a appears to be correlated with the progression, occurrence and poor prognosis in patients with breast, gastric or ovarian cancer.\(^22\),\(^23\) However, many studies have also revealed that overexpression of FOXO3a was associated with poor prognosis in breast cancer and glioblastoma.\(^24\),\(^25\) Therefore, it is still controversial and requires further studies to reveal the exact role of FOXO3a in human cancers.

A recent study has shown that FOXO3a can be regulated by simvastatin, and FOXO3a expression levels are correlated with metastasis-free survival in patients with breast cancer.\(^26\) However, the mechanism of how FOXO3a is regulated and its role in cancer cell progression by statins is still unclear. Therefore, present study was performed with the aim to evaluate the anticancer effect of statins and elucidate the molecular mechanism by which statins regulate FOXO3a in OSCCs.

## 2 | MATERIALS AND METHODS

### 2.1 | Chemicals and reagents

AICAR, compound C, eosin, haematoxylin, 4',6-diamidino-2-phenylindole (DAPI), dimethyl sulfoxide (DMSO) and crystal violet were obtained from Sigma-Aldrich (St. Louis, MO, USA). Simvastatin was purchased from LKT Laboratories, Inc (St. Paul, MN, USA), and pitavastatin calcium was purchased from HL Genomics (Gyeonggi-Do, Republic of Korea). LY294002 and antibodies against p-Akt (Ser437), Akt, p-AMPK (Tyr172), AMPK, p-FOXO3a (Ser253, Ser413), FOXO3a, PUMA, Caspase-3, Caspase-9, PARP, E-cadherin, N-cadherin, vimentin, β-catenin, ZEB1, Snail2 and Lamin B1 were purchased from Cell Signaling Technology (Beverly, MA, USA), and GAPDH was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A secondary antibody conjugated to horseradish peroxidase was procured from Thermo Fisher Scientific (Rockford, IL, USA).

### 2.2 | Cell lines and cell culture

Human OSCCs, SCC4 and SCC15, were obtained from American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12=1:1) supplemented with 10% FBS (HyClone Laboratories, Logan, UT, USA) and 1% penicillin/streptomycin at 37°C in a humidified incubator with 5% CO\(_2\).

### 2.3 | RNA interference

Double-stranded siRNAs against human FOXO3a (NM_001455.3), Akt (NM_001014431.1), AMPK (NM_001355028.1), PUMA (NM_001127240.2) were synthesized by Bioneer (Daejeon, Republic of Korea). Negative control siRNA was obtained from Bioneer (Cat.
No.: SN-1003). The sequence for siRNA duplexes used in this study are as follows: AKT: forward, 5'- GAC AAC CGC CAU CCA GAC U-3'; reverse, 5'- AGU CUG GAU GGC GGU UGU C-3'; AMPK: forward, 5'- CUG AGU UGC AUA UAC UGU A-3'; reverse, 5'- UAC AGU AUA UGC AAC UCA G-3'; FOXO3a: forward, 5'- CUA UCA UAU GGC AUU CUU A-3'; reverse, 5'- UAA GAA UGC CAU AUG AUA G-3'; PUMA: forward, 5'- GUA GAU ACC GGA AUG AAU U-3'; reverse, 5'- AAU UCA UUC CGG UAU CUA C-3'. SCC15 cells were seeded at 1.5 × 10^5 cells/well in 96-well microplates and incubated overnight. At the end of the drug treatment, cells were incubated with a luminogenic substrate Z-DEVD-NH in presence of caspase-3/7 protease using a luminescence that was generated from the cleavage of luminogenic substrate, and caspase-3/7 activity was determined by measuring the luminescence that was generated from the cleavage of luminogenic substrate Z-DEVD-NH in presence of caspase-3/7 protease using a micro-plate reader.

2.4 | Caspase-3/7 activity assay

Caspase-3/7 activity was assessed using the Caspase-Glo 3/7 assay kit (Promega Corporation, Madison, WI, USA) according to the manufacturer's instructions. In brief, cells were seeded at 1.5 × 10^5 cells/well in 96-well microplates and incubated overnight. At the end of the drug treatment, cells were incubated with a luminogenic substrate, and caspase-3/7 activity was determined by measuring the luminescence that was generated from the cleavage of luminogenic substrate Z-DEVD-NH in presence of caspase-3/7 protease using a micro-plate reader.

2.5 | Western blot analysis

Cell lines were distributed at 1 × 10^6 cells/100 mm dish. After appropriate treatments, total cellular extracts were prepared using radio-immunoprecipitation assay lysis buffer (RIPA) containing a Halt Protease Inhibitor Cocktail (Thermo Scientific). Next, 30-40 µg of total proteins were loaded onto 6-12% sodium dodecyl sulphate (SDS)-polyacrylamide gel, separated by electrophoresis and transferred to PVDF membranes. Possible non-specific binding was blocked by incubation with 5% BSA in TBS-T for 1 hour and then incubated overnight at 4°C with specific primary antibodies. Membranes were then washed with TBS-T four times, followed by incubation with secondary antibodies conjugated with horseradish peroxidase for 1 hour and washed with TBS-T three times in 10 minutes intervals. Finally, images of proteins were captured using LAS-3000 (Fuji, Tokyo, Japan).

2.6 | Statistical analyses

Data were analysed by Student's t test or one-/two-way ANOVA using GraphPad Prism 5. All data are presented as mean ± SD

P < 0.05 was considered statistically significant.

3 | RESULTS

3.1 | Pitavastatin inhibits metastatic properties in human oral squamous SCC15 cells

Our previous study revealed that SCC15 cells exhibit a typical mesenchymal phenotype and a higher dependency on aerobic glycolysis compared to other OSCC cell lines we tested. Therefore, it is highly desirable to find an effective anticancer drug using this cell line model. In this study, we analysed the anticancer effect of statins, such as simvastatin and pitavastatin, on SCC4 and SCC15 human OSCC cells. To measure the expression pattern of epithelial-mesenchymal transition (EMT) markers, cells were incubated with antibodies against E-cadherin, N-cadherin and vimentin and counter-stained with DAPI. Immunofluorescent cells were then observed by fluorescence microscopy. As shown in Figure 1A, the expression of epithelial markers E-cadherin was lower in SCC15 cells compared to SCC4 cells, whereas mesenchymal markers N-cadherin and vimentin were highly expressed in SCC15 cells compared to SCC4 cells, confirming the different epithelial and mesenchymal nature between two OSCC cell lines and this pattern is consistent with previous publication. As shown in Figure 1B, the treatment of both cells with pitavastatin and simvastatin for 48 hours significantly decreased cell viability in SCC15 cells but not in SCC4 cells. Among these statins, 0.5 µmol L^{-1} of pitavastatin inhibited cell viability by more than 50%, whereas simvastatin inhibited only about 10% at the same concentration in SCC15 (Figure 1B). Furthermore, the protein expression of mesenchymal markers such as β-catenin, N-cadherin, ZEB1 and snail2 was markedly decreased by treatment with pitavastatin in SCC15 cells, but not in SCC4 cells (Figure 1C). Based on these results, pitavastatin seems to be effective in SCC15 cells, and thus further experiments were conducted using pitavastatin. We also found that pitavastatin decreased the invasion and migration of SCC15 cells without affecting cell viability at 24 h (Figure 1D). As shown in Figure 1E, 0.05 µmol L^{-1} of pitavastatin decreased the migration and invasion by about 16% and 6.3%, respectively. Next, the effect of pitavastatin on the PCC15 cells was measured. The results showed that colony formation was significantly suppressed by pitavastatin treatment (Figure 1F). Taken together, these results indicate that pitavastatin decreases cell viability and inhibits metastatic properties such as EMT, migration and invasion in SCC15 cells.

3.2 | Pitavastatin selectively induces apoptosis in SCC15 cells

Next, we assessed the effect of pitavastatin on the induction of apoptosis by assessing for Annexin V-positive cells via flow cytometry analysis. Our data revealed that pitavastatin did not induce apoptosis in SCC4 cells, whereas treatment with pitavastatin at a concentration of 0.1 µmol L^{-1} and 0.25 µmol L^{-1} increased
apoptosis by 31% and 53%, respectively, in SCC15 cells (Figure 2A).
Furthermore, pitavastatin-induced caspase-3/7 activity in SCC15
cells but not in SCC4 cells (Figure 2B), which was consistent with
the results obtained from the flow cytometry analysis. The apopto-
tic effect of pitavastatin was further confirmed by Western blot
analyses showing that the cleaved form of caspase-3 and PARP
were significantly increased by pitavastatin in a dose-dependent
manner (Figure 2C). These results altogether suggest that pitava-
satin selectively induces apoptosis in SCC15 cells, but not in SCC4
cells.

### 3.3 Pitavastatin promotes translocation of FOXO3a by regulating AMPK and Akt signalling

Simvastatin has been shown to induce apoptosis and inhibit EMT
via suppression of PI3K/Akt signalling, thereby resulting in radiosen-
sitivity in radioresistant oesophageal cancer cells. In addition,
other studies have shown that AMPK activation by lovastatin caused
cytotoxicity and induced apoptosis of cancer cells such as OSCC and
lung cancers. Thus, we explored the possibility of whether Akt
and AMPK signalling could be involved in pitavastatin-mediated
We have previously observed a higher level of phosphorylated-Akt and lower level of phosphorylated-AMPK in SCC15 cells compared to SCC4 cells. We hypothesized that Akt and AMPK might be the possible regulatory proteins involved in the anticancer effects mediated by pitavastatin in SCC15 cells. Interestingly, no changes in the phosphorylation of Akt and AMPK were observed by treatment with pitavastatin in SCC4 cells, but the phosphorylated-Akt level was decreased while the phosphorylated-AMPK level was increased by pitavastatin in a dose-dependent manner in SCC15 cells. FOXO3a, a transcription factor regulating the transcription of diverse genes involved in apoptosis, has been known to be regulated by several upstream kinases including Akt and AMPK. Several reports have suggested that the phosphorylation of FOXO3a by Akt at serine 253 (S253) resulted in its export into the cytosol and subsequent inactivation, whereas phosphorylation of FOXO3a by AMPK at serine 256 (S256) resulted in its inactivation. However, the exact mechanism by which Akt and AMPK regulate FOXO3a remains unclear. Further studies are needed to elucidate the role of Akt and AMPK in the regulation of FOXO3a and their potential as therapeutic targets for the treatment of cancer.
AMPK phosphorylates FOXO3a at serine 413 (S413), thereby leading to nuclear translocation and ultimately induces its target genes to regulate cancer cell death. Therefore, we assessed the expression and phosphorylation of FOXO3a as a downstream signalling molecule of Akt and AMPK. Unlike SCC4 cells, which expresses low levels of FOXO3a, the already high basal levels of Foxo3a was increased after pitavastatin treatment in SCC15 cells, which was correlated with induction of apoptosis (Figure 3A). Interestingly, the phosphorylation of FOXO3a at S413 and S253 increased and decreased, respectively, by pitavastatin, which was consistent with the observed phosphorylated levels of AMPK and Akt (Figure 3A). Furthermore, the nuclear translocation of FOXO3a was examined by Western blotting and confocal microscopy. As shown in Figure 3B, the nuclear localization of FOXO3a was prominently increased by treatment with 0.05 µmol L⁻¹ of pitavastatin. The nuclear translocation of FOXO3a was also confirmed by immunocytochemistry, where FOXO3a was condensed into the nucleus after pitavastatin treatment (Figure 3C). These results altogether confirmed that pitavastatin increased the activity of FOXO3a by increasing its phosphorylation and nuclear translocation. Next, we investigated the role of Akt and AMPK in the activation of FOXO3a by knockdown of their respective genes. As shown in Figure 3D (upper panel), the decrease in p-FOXO3a (S253) as well as the increase in p-FOXO3a (S413) by pitavastatin was further enhanced by gene silencing of Akt, respectively. The increase in p-FOXO3a (S413) by gene silencing of Akt might have resulted from the inhibition of FOXO3a degradation.
because Akt-mediated phosphorylation at S253 of FOXO protein facilities the binding by 14-3-3 protein or Skp2 leading to its degradation. Opposite to the effect of Akt silencing, an increase in p-FOXO3a (S253) and a decrease in p-FOXO3a (S413) by pitavastatin were observed after AMPK gene silencing (Figure 3D, lower panel). Furthermore, modulation of FOXO3a activation by Akt and AMPK signalling was confirmed by measuring the amount of FOXO3a expression in the nucleus after gene silencing of Akt or AMPK in the presence or absence of pitavastatin for 48 hours, and caspase-3/7 activity was measured by Caspase-3/7 activity assay kit. Statistical analysis was performed by two-way ANOVA. Error bars represent mean ± SD (n = 4). ***P < 0.001 vs CON.
3.4 | Akt/AMPK signalling is involved in the induction of apoptosis by pitavastatin in SCC15 cells

As apoptosis is regarded as a major determinant of cell viability, we checked if pitavastatin-mediated suppression of cell viability and induction of apoptosis might be the results of dual regulation of Akt and AMPK. The suppression of cell viability (Figure 4A) and activation of caspase-3/7 (Figure 4B) by pitavastatin were further enhanced by siAkt compared with siCON. Furthermore, as shown in Figure 4C, induction of all the apoptotic markers such as PUMA, cleaved caspase-3/9 and cleaved-PARP by pitavastatin was further enhanced by siAkt. The role of Akt in apoptosis was further confirmed by measuring caspase-3/7 activity by using the well-known PI3K inhibitor LY294002, where an increase in caspase-3/7 activity by pitavastatin was further enhanced by LY294002 pre-treatment (Figure 4G), consistent with the result obtained by gene silencing of Akt (Figure 4B). These results suggest that Akt negatively regulates the apoptotic process, and suppression of Akt signalling could be a promising strategy for the treatment of oral cancer cells by pitavastatin. In addition, gene silencing of AMPK significantly abrogated the suppression of cell viability (Figure 4D) and inhibited the activation of caspase-3/7 (Figure 4E) by pitavastatin. Similarly, the expression of apoptotic markers by pitavastatin was significantly suppressed by AMPK gene knockdown (Figure 4F). A similar result was obtained by using the well-known AMPK activator AICAR (Figure 4H). These results further confirm that AMPK is involved in the suppression of cell viability and induction of apoptosis by pitavastatin in SCC15 cells.

3.5 | Pitavastatin induces apoptosis through FOXO3a/PUMA signalling

Next, we determined whether FOXO3a regulated by Akt and AMPK could modulate apoptosis in SCC15 cells. Our data revealed that the suppression of cell viability and activation of caspase-3/7 by pitavastatin were abrogated by gene silencing of FOXO3a (Figure 5A,B). As we expected, the expression level of apoptotic markers was lower...
in the siFOXO3a group than in the siCON group (Figure 5C). These results strongly suggest that FOXO3a is involved in the pitavastatin-mediated apoptotic process in SCC15 cells. FOXO3a is a transcription factor that can regulate both extrinsic and intrinsic apoptosis pathway especially by transcribing FasL (extrinsic) and Bim or PUMA (intrinsic). Statins have been shown to induce apoptosis via down-regulation of anti-apoptotic protein Bcl-2 rather than up-regulation of Fasl or p53, supporting the notion that statins can mediate apoptosis via the intrinsic pathway. When we measured the expression of Bim and PUMA after the pitavastatin treatment, which are the proteins involved in the intrinsic apoptotic pathway, PUMA was found to be increased by pitavastatin in a dose-dependent manner while Bim was not changed (data not shown). Thus, PUMA was selected as a target gene of FOXO3a involved in the induction of intrinsic apoptosis. Like FOXO3a, gene silencing of PUMA significantly abrogated the suppression of cell viability and inhibited the activation of caspase-3/7 by pitavastatin (Figure 5D,E). Consistently, knockdown of PUMA resulted in a significant decrease in pitavastatin-induced expression of apoptotic markers (Figure 5F). Taken together, these results confirm that FOXO3a-mediated PUMA induction was dominantly involved in a reduction of cell viability and induction of apoptosis by pitavastatin in SCC15 cells.

4 | DISCUSSION

Recent drug repositioning studies have revealed the anticancer effect of statins in different types of cancer. Moreover, many studies have been conducted to elucidate their mechanism of action in various cancer cells. The main anticancer mechanism of statins is the inhibition of the mevalonate pathway, which is essential in the maintenance of cellular functions such as cell membrane integrity, cell cycle progression and protein synthesis and the inhibition of which leads to the suppression of cancer growth and progression. Another report indicates that the treatment of metastatic mouse melanoma cells with simvastatin and fluvastatin inhibits cell growth and metastasis via suppression of matrix metalloproteinases (MMPs), very late antigens (VLAs) and Rho prenylation, which are crucial for cell cycle progression and cell motility. In this experimental model, the cell cycle arrest was enhanced via the up-regulation of cell cycle regulators such as p53, p27 and p21. Fluvastatin induces apoptosis of HSC-3, an OSCC cell and that was found to be mediated via the inhibition of HMG-CoA reductase leading to suppression of geranylgeranyl pyrophosphate (GGPP) biosynthesis; a substrate of the mevalonate pathway, and ERK1/2 phosphorylation. Also, simvastatin induces apoptosis in a mouse model of osteosarcoma via activation of AMPK/p38MAPK signalling, which is dependent on the inhibition of the mevalonate pathway. A recently developed statin, pitavastatin, exhibits anticancer effect synergistically with prednisolone or with pictilisib in ovarian cancer cells.

In the present study, the anticancer effect of statin, particularly pitavastatin was confirmed in SCC15 cells while almost no effect was observed in SCC4 cells. This can imply that the higher selectivity of pitavastatin in SCC15 between two OSCC might be related in part to the higher aggressiveness, invasiveness and metastatic nature of SCC15 compared to SCC4. Consistent with our previous data, we observed the low expression of E-cadherin and high expression of N-cadherin and vimentin in SCC15 cells compared to SCC4 cells (Figure 1A). The higher expression of N-cadherin and vimentin denotes that SCC15 cells are more invasive and metastatic than SCC4 cells. Interestingly, our data indicated that pitavastatin shows a better potency in SCC15 cells compared to SCC4 cells. One possibility of differential sensitivity of SCC15 towards statin might be due to the higher expression of FOXO3a and its upstream kinases such as Akt and AMPK in SCC15 cells. The different patterns of Akt and AMPK modulation by pitavastatin (Figure 3A) might be one of the reasons. It is well known that activation of Akt is important in cancer cell proliferation and progression, whereas activation of AMPK is important in the suppression of tumour progression. Pitavastatin did not induce the activation of Akt, AMPK and FOXO3a in SCC4 cells but it decreased Akt phosphorylation while increased AMPK and FOXO3a phosphorylation as well as FOXO3a expression in SCC15 cells (Figure 3A). Our data demonstrated that the high basal expression of FOXO3a was maintained and, increased by the treatment with pitavastatin in SCC15 cells, but not in SCC4 cells. It is noteworthy that the differential activation of Akt and AMPK between the two OSCCs by pitavastatin might be crucial in the regulation of FOXO3a.

The protein activity and biological role of FOXO3a are determined by post-translational modifications, including phosphorylation, acetylation and ubiquitination. AMPK phosphorylates FOXO3a at six positions (Thr179, Ser399, Ser413, Ser439, Ser555 and Ser588), which then leads to the transcription of various genes. AMPK-mediated FOXO3a activation has been shown to induce cell cycle arrest and apoptosis in breast cancer cells and hepatoma cancer cells. FOXO3a activation induced by the inhibition of PI3K/Akt is involved in cisplatin-induced cytotoxicity in several cancers such as colorectal, lung and OSCC, suggesting that drugs that deactivate PI3K/Akt could be a promising anticancer therapy. In the present study, our data also revealed that the suppression of cell viability and activation of caspase-3/7 by pitavastatin was additively enhanced by silencing of Akt (Figure 4A-C). According to Figure 3D, the decrease in p-FOXO3a (S253) and increase in p-FOXO3a (S413) by pitavastatin was further enhanced by the silencing of Akt (Figure 3D). Akt signalling is well known to mediate cancer cell proliferation and tumour growth. For example, HBP1 induction by ROS scavenger, NAC, decreases cell viability and induces apoptosis in oral cancer cells and this effect was mediated by inhibition of Akt activation. Further, induction of cell death by an anti-oxidant, quercetin, is mediated by inhibition of PI3K/Akt/mTOR, Wnt/β-catenin and STAT pathways. Furthermore, miRNA-21 (miR-21) inhibits PTEN/Akt/GSK3 signalling axis to inhibit lung cancer cell proliferation and EMT. In our experimental model as well, gene silencing of Akt further enhanced the suppression of cell viability and activation of caspase-3/7 by pitavastatin and it shows that pitavastatin and Akt gene knockdown act to an additive mechanism. Thus, it can be assumed that the additive mechanism by gene silencing of Akt
in pitavastatin-treated condition might be due to the inhibition of other signalling pathways such as Akt/HBP1, PI3K/Akt/mTOR and Akt/GSK3 in addition to Akt-FOXO3a signalling. Therefore, we reasoned that the (a) inhibition of Akt activation by pitavastatin seems to be incomplete and (b) other pathways as well as Akt-FOXO3a can be contributed to an additive mechanism by pitavastatin and gene silencing of Akt.

Our data suggest a molecular mechanism by which statins induces anticancer activity by modulating FOXO3a. Pitavastatin induces nuclear translocation of FOXO3a by inhibiting Akt and activating AMPK, which results in the induction of PUMA, causing cancer cell death (Figure 6). It has been accepted that the activation of FOXO3a inhibits the propagation, tumour formation and invasive nature of cancer, while inhibition of its activation induces tumour formation. Many anticancer drugs have been found to target FOXO3a protein. For example, paclitaxel and KP372-1 (a multiple kinase inhibitor) activate FOXO3a by reducing Akt activation, thereby leading to cancer apoptosis. Also, drugs such as trastuzumab and cetuximab activate FOXO3a to induce apoptosis in mouse melanoma models. Consistent with this, in this study, we also demonstrated that the Akt/FOXO3a and AMPK/FOXO3a axes are directly involved in statin-induced apoptosis in OSCCs.

Apoptosis is normally triggered by two main pathways: extrinsic, which is mediated by the activation of death receptors (Fas and TNFR) and subsequent activation of caspase-8, and intrinsic, which is mediated by the mitochondria and subsequent activation of caspase-9. Both the extrinsic and intrinsic pathways result in PARP activation, thereby leading to cell death. Of note, FOXO3a has been known to induce both apoptotic pathways. It has been shown that FOXO3a mediates extrinsic apoptosis via transcriptionally up-regulating FasL and induces intrinsic apoptosis by increasing the expression of proapoptotic Bcl-2 family members such as Bim and PUMA. These proteins activate caspase-9, leading to the cleavage of caspase-3/7 and subsequent widespread cell death. A previous study has observed that apoptosis induced by atorvastatin and fluvastatin was found to be dependent on the regulation of anti-apoptotic protein Bcl-2 rather than up-regulation of FasL or p53.

Our study also revealed that pitavastatin induces oral cancer cell apoptosis via FOXO3a-mediated up-regulation of PUMA, which leads to the activation of caspase-3/9 (Figure 5), suggesting that the intrinsic apoptosis pathway is regulated by statins.

Collectively, by investigating the anticancer activity of statin in OSCCs, it was confirmed that the transcriptional activity of FOXO3a is increased by the regulation of Akt and AMPK activity, which leads to the induction of intrinsic apoptosis in OSCC. Therefore, we propose that statins can be used as anticancer agents, and the effect of statin is mainly due to the Akt/FOXO3a or AMPK/FOXO3a axis.

ACKNOWLEDGEMENTS
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (Grant no. NRF-2016R1A6A1A03011325, NRF-2018R1D1A3B07048623).

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Won-Jun Jang https://orcid.org/0000-0001-6598-0810
Chul-Ho Jeong https://orcid.org/0000-0003-4709-3497

REFERENCES
1. Wang H, Naghavi M, Allen C, et al.; GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249
causes of death, 1980–2015; a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388:1549-1544.
2. Osman TA, Costea DE, Johannessen AC. The use of salivary cyto-
kines as a screening tool for oral squamous cell carcma: a review of the literature. J Oral Maxillofac Pathol. 2012;16:256-261.
3. Takes RP, Rinaldo A, Silver CE, et al. Distant metastases from head
and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol.
2012;48:775-779.
4. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: prog-
ress, challenges and recommendations. Nat Rev Drug Discovery.
2019;18:41-58.
5. Wurth R, Thellung S, Bajetto A, Mazzanti M, Florio T, Barbieri
F. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov Today.
2016;21:190-199.
6. Bansal D, Undela K, D'Cruz S, Schifano F. Statin use and risk of pros-
tate cancer: a meta-analysis of observational studies. PLoS ONE.
2012;7:e46691.
7. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23:8606-8612.
8. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10-19.
9. Gupta A, Stokes W, Eguchi M, et al. Statin use associated with im-
proved overall and cancer specific survival in patients with head and neck cancer. Oral Oncol. 2019;90:54-66.
10. Brewer TM, Masuda H, Liu DD, et al. Statin use in primary inflamma-
tory breast cancer: a cohort study. Br J Cancer. 2013;109:318-324.
11. Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer cell
growth and survival, via involvement of Akt signaling. PLoS ONE. 2018;13:e0197422.
12. Kobayashi Y, Kashima H, Rahmanto YS, et al. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian car-
cer. Oncotarget. 2017;8:72147-72156.
13. Kamel WA, Sugihara E, Nobusue H, et al. Simvastatin-induced apop-
tosis in osteosarcoma cells: a key role of RhoA-AMPK-p38 MAPK signaling in antitumor activity. Mol Cancer Ther. 2017;16:182-192.
14. Wang ST, Ho HJ, Lin JT, Shieh JJ, Wu CY. Simvastatin-induced cell
cycle arrest through inhibition of STAT3/SPK2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017;8:e2626.
15. Wang T, Seah S, Loh X, et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 2016;7:2532-2544.
16. Myatt SS, Lam EW. The emerging roles of forhead box (Fox) pro-
teins in cancer. Nat Rev Cancer. 2007;7:847-859.
17. Wang X, Hu S, Liu L. Phosphorylation and acetylation modific-
aions of FOXO3a: independently or synergistically? Oncol Lett.
2017;13:2867-2872.
18. Link W, Fernandez-Marcos PJ. FOXO transcription factors at the in-
terface of metabolism and cancer. Int J Cancer. 2017;141:2379-2391.
19. Akhter R, Sanphui P, Biswas SC. The essential role of p53-up-regu-
lated modulator of apoptosis (Puma) and its regulation by FoxO3a transcription factor in beta-amyloid-induced neuron death. J Biol Chem. 2014;289:10812-10822.
20. Sunters A, Fernandez de Mattos S, Stahl M, et al. FoxO3a transcription-
regulatory function of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 2003;278:49795-49805.
21. Fei M, Zhao Y, Wang Y, et al. Low expression of Foxo3a is associ-
ated with poor prognosis in ovarian cancer patients. Cancer Invest.
2009;27:52-59.
with pitavastatin to induce ovarian cancer cell death. Sci Rep. 2019;9:9632.

44. De Wolf E, De Wolf C, Richardson A. ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells. Oncol Lett. 2018;15:1979-1984.

45. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.

46. Choi YH. ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells. Gen Physiol Biophys. 2018;37:129-140.

47. Calnan DR, Brunet A. The FoxO code. Oncogene. 2008;27:2276-2288.

48. Queiroz EA, Puukila S, Eichler R, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS ONE. 2014;9:e98207.

49. Shrestha A, Nepal S, Kim MJ, et al. Critical role of AMPK/FOXO3a axis in globular adiponectin-induced cell cycle arrest and apoptosis in cancer cells. J Cell Physiol. 2016;231:357-369.

50. Fernandez de Mattos S, Villalonga P, Clardy J, Lam EW. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther. 2008;7:3237-3246.

51. Liu H, Yin J, Wang C, Gu Y, Deng M, He Z. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells. Anticancer Drugs. 2014;25:898-907.

52. Lee MF, Chan CY, Hung HC, Chou IT, Yee AS, Huang CY. N-acetylcysteine (NAC) inhibits cell growth by mediating the EGFR/Akt/HMG box-containing protein 1 (HBPI) signaling pathway in invasive oral cancer. Oral Oncol. 2013;49:129-135.

53. Granato M, Rizzello C, Gilardini Montani MS, et al. Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. J Nutr Biochem. 2017;41:124-136.

54. Dai L, Chen F, Zheng Y, et al. miR-21 regulates growth and EMT in lung cancer cells via PTEN/Akt/GSK3beta signaling. Front Biosci (Landmark Edition). 2019;24:1426-1439.

55. Sunters A, Madureira PA, Pomeranz KM, et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Can Res. 2006;66:212-220.

56. Zeng Z, Samudio IJ, Zhang W, et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Can Res. 2006;66:3737-3746.

57. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochem Biophys Acta. 2011;1813:1978-1986.

58. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol. 2003;162:613-622.

How to cite this article: Lee N, Tilija Pun N, Jang W-J, Bae JW, Jeong C-H. Pitavastatin induces apoptosis in oral squamous cell carcinoma through activation of FOXO3a. J Cell Mol Med. 2020;24:7055-7066. https://doi.org/10.1111/jcmm.15389